goat anti human il 17a polyclonal antibody  (R&D Systems)

Journal: Clinical Medicine Insights. Oncology

Article Title: Th9 and Th17 Cells in Human Ulcerative Colitis-Associated Dysplastic Lesions

doi: 10.1177/11795549241301358

Figure Lengend Snippet: Immunohistochemical (IHC) photographic presentation of CD3-positive T lymphocytes, PU.1-positive Th9, and IL-17A-positive Th17 cells in human UC and colitis-associated dysplastic tissues. Microscopic photos from the control sections showed that CD3-positive T lymphocytes were primarily observed in the lamina propria (black arrow-pointed cells in A), and intraepithelial CD3-positive T lymphocytes were also fund (black arrowhead-pointed cell in inserted enlarged image in A). As expected, increased CD3-positive T lymphocytes in the lamina propria (black arrow-pointed cells) and epithelium (black arrowhead-pointed cells in inserted enlarged images) were shown in both the UC (B) and colitis-associated dysplastic (C for ALD and D for NALD) sections. Microscopic photos of PU.1 IHC sections showed that increased PU.1-positive Th9 cells were observed in the lamina propria (black arrow-pointed cells) and epithelium (black arrowhead-pointed cells in inserted enlarged images) in both UC (F) and colitis-associated dysplastic (G for ALD and H for ALD) sections relative to the control section (E). Similarly, microscopic photos of IL-17A IHC sections showed that IL-17A-positive Th17 cells were increased in both the lamina propria (black arrow-pointed cells) and epithelium (black arrowhead-pointed cells in inserted enlarged images) in the UC (J) and colitis-associated dysplastic (K for ALD and L for NALD) sections as compared with the control section (I) (A to L IHC images, counterstained with hematoxylin, original magnification ×200). ALD indicates adenoma-like dysplasia; NALD, non-adenoma-like dysplasia; UC, ulcerative colitis.

Article Snippet: 1 polyclonal antibody (purchased from LifeSpan BioSciences Inc, Seattle, WA, USA) to label Th9 cells and goat anti-human IL-17A polyclonal antibody (Catalog No: AF-317-NA, clone Ile20Ala155, purchased from R&D System; Minneapolis, MN, USA) to label Th17 cells.

Techniques: Immunohistochemical staining, Control

Journal: Clinical Medicine Insights. Oncology

Article Title: Th9 and Th17 Cells in Human Ulcerative Colitis-Associated Dysplastic Lesions

doi: 10.1177/11795549241301358

Figure Lengend Snippet: Graph analysis of density grading scores of CD3-positive T lymphocytes, PU.1-positive Th9, and IL-17A-positive Th17 subset cells in human colitis-associated dysplastic tissues. Graphic statistical analysis of CD3-positive T lymphocytes, PU.1-positive Th9, and IL-17A-positive Th17 cells revealed that densities of CD3-positive T lymphocytes (A for positive cells in the lamina propria, B for positive cells in the epithelium), PU.1-positive Th9 cells (C for positive cells in the lamina propria, D for positive cells in the epithelium) and IL-17A-positive Th17 cells (E for positive cells in the lamina propria) were significantly increased in both the UC (gray bar) and UC-associated ALD (grid bar) and NALD (black bar) as compared with control (white bar, all P < .01 from the Kruskal-Wallis test). Interestingly, densities of PU.1-positive Th9 cells in both the lamina propria and epithelium of the NALD group were greatly higher than the UC group (refer to C and D, both P < .05 from the Mann-Whitney test) and the density of IL-17A-positive Th17 cells in the lamina propria of the NALD group was higher than that the UC group ( P < .05 from the Mann-Whitney test). However, densities of these cells were non-statistically changed ( P > .05), except the density of intraepithelial CD3-positive T lymphocytes (B, P < .05 from the Mann-Whitney test), between the ALD (grid bar) and NALD (black bar) in colitis-associated dysplastic sections (refer to F). ALD indicates adenoma-like dysplasia; NALD, non-adenoma-like dysplasia; UC, ulcerative colitis.

Article Snippet: 1 polyclonal antibody (purchased from LifeSpan BioSciences Inc, Seattle, WA, USA) to label Th9 cells and goat anti-human IL-17A polyclonal antibody (Catalog No: AF-317-NA, clone Ile20Ala155, purchased from R&D System; Minneapolis, MN, USA) to label Th17 cells.

Techniques: Control, MANN-WHITNEY

Journal: Respiratory Research

Article Title: Interleukin-17A mRNA and protein expression within cells from the human bronchoalveolar space after exposure to organic dust

doi: 10.1186/1465-9921-6-44

Figure Lengend Snippet: Messenger RNA for IL-17A in BAL cells . Messenger RNA for IL-17A in BAL cells (percentage of the house-keeping gene HPRT), measured 2 weeks before and 24 hours after exposure to organic dust in a swine confinement. Data are shown as individual (rhombs) plus median (bold horizontal lines) values. *: p < 0,0167; n = 6

Article Snippet: The intracellular expression of IL-17A protein was assessed utilising cytospin slides incubated with a polyclonal goat anti-human IL-17A antibody (R&D: 1 hr).

Techniques:

Journal: Respiratory Research

Article Title: Interleukin-17A mRNA and protein expression within cells from the human bronchoalveolar space after exposure to organic dust

doi: 10.1186/1465-9921-6-44

Figure Lengend Snippet: Immunocytochemical detection of IL-17A protein in BAL lymphocytes . BAL lymphocytes expressing IL-17A IR (brown arrows) after exposure to organic dust in a swine confinement, detected using immunocytochemistry.

Article Snippet: The intracellular expression of IL-17A protein was assessed utilising cytospin slides incubated with a polyclonal goat anti-human IL-17A antibody (R&D: 1 hr).

Techniques: Expressing, Immunocytochemistry

Journal: Respiratory Research

Article Title: Interleukin-17A mRNA and protein expression within cells from the human bronchoalveolar space after exposure to organic dust

doi: 10.1186/1465-9921-6-44

Figure Lengend Snippet: BAL lymphocytes expressing IL-17A protein . Percentage of BAL lymphocytes expressing IL-17A IR before and after the exposure to organic dust in a swine confinement. Data are shown as individual (rhombs) plus median (bold horizontal lines) values. NS: p > 0,0167; n = 6

Article Snippet: The intracellular expression of IL-17A protein was assessed utilising cytospin slides incubated with a polyclonal goat anti-human IL-17A antibody (R&D: 1 hr).

Techniques: Expressing

Journal: Clinical and Developmental Immunology

Article Title: Expression of IL-17, IL-23 and Their Receptors in Minor Salivary Glands of Patients with Primary Sjögren's Syndrome

doi: 10.1155/2012/187258

Figure Lengend Snippet: Expression of IL-17 and IL-17R in minor salivary glands of patients with pSS, probable preclinical pSS, and nonautoimmune sicca syndrome. IL-17: (a) pSS, (b) probable preclinical pSS, (c) nonautoimmune sicca syndrome. IL-17R: (d) pSS, (e) probable preclinical pSS, (f) nonautoimmune sicca syndrome, (g) negative staining control. Counterstained with hematoxylin. Original magnification ×400. Abbreviations: A: acinus, Adip-adipocytes, Bv: blood vessel, D: ductus, and Ly: lymphocyte infiltration.

Article Snippet: Primary antibodies were used: rabbit anti-human IL-17 (H-132) polyclonal antibody, 2 μ g/mL (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA); goat anti-human IL-17 RD/SEF receptor polyclonal IgG, 4 μ g/mL (R&D Systems, Minneapolis, MN, USA); mouse anti-human IL-23 (p19) monoclonal IgG1, κ , 4 μ g/mL (BioLegend, San Diego, CA, USA); goat anti-human IL-23 receptor polyclonal antibody, 4 μ g/mL (Capralogics, Inc. Hardwick, MA, USA).

Techniques: Expressing, Negative Staining

Journal: Biomedicines

Article Title: Reduced Interleukin-17-Expressing Cells in Cutaneous Melanoma

doi: 10.3390/biomedicines9121930

Figure Lengend Snippet: Demographic, histological, and clinical characteristics of patients and IL-17A levels.

Article Snippet: The following primary antibodies were used for staining: anti-human CD3 rabbit polyclonal antibody (A0452, Dako, Glostrup, Denmark), at a concentration of 6 μg/mL; anti-human IL-17A goat polyclonal antibody (AF-317-NA, R&D Systems, Minneapolis, MN, USA), at 1:20 dilution; anti-human placenta growth factor (PlGF) rabbit polyclonal antibody (clone 1880, Santa Cruz Biotechnology, Santa Cruz, CA, USA), at 1:50 dilution.

Techniques:

Journal: Biomedicines

Article Title: Reduced Interleukin-17-Expressing Cells in Cutaneous Melanoma

doi: 10.3390/biomedicines9121930

Figure Lengend Snippet: TIL clones isolated from melanoma biopsies were analyzed for ( A ) CD4 and CD8; ( B ) TNF-α, IFN-γ; ( C ) IL-4 and IL-8; ( D ) IL-17A; ( E ) IL-22 expression by flow cytometry. Results are shown as the mean of the percentage ± standard error of the mean (SEM) of the data from the seven patients. In ( D , E ), the percentage of positive TILs from the melanoma biopsies was compared with that of the PBMCs from the same patient or with that of TILs isolated from BCCs. * p < 0.05; Student’s t -test.

Article Snippet: The following primary antibodies were used for staining: anti-human CD3 rabbit polyclonal antibody (A0452, Dako, Glostrup, Denmark), at a concentration of 6 μg/mL; anti-human IL-17A goat polyclonal antibody (AF-317-NA, R&D Systems, Minneapolis, MN, USA), at 1:20 dilution; anti-human placenta growth factor (PlGF) rabbit polyclonal antibody (clone 1880, Santa Cruz Biotechnology, Santa Cruz, CA, USA), at 1:50 dilution.

Techniques: Clone Assay, Isolation, Expressing, Flow Cytometry

Journal: Biomedicines

Article Title: Reduced Interleukin-17-Expressing Cells in Cutaneous Melanoma

doi: 10.3390/biomedicines9121930

Figure Lengend Snippet: Multiplex immunofluorescence analysis of the first panel. ( a ) Representative 7-color multispectral image of the first multiplex immunofluorescence panel. Markers and color codes are indicated above the figure. Original magnification 20×. Right panels: crops showing only CD3+ (magenta), CD4+ (yellow) and IL-17A+ (white) cells. Density (number of cells/mm 2 ) of total CD3+ and CD3+CD4+ cells ( b ), CD56+ cells and Neutrophil elastase+ (NE+) cells ( c ), total IL-17A+ cells, CD4+IL-17A+ and total CD4+ cells ( d ) was quantified in the stroma (left panels) and in the intra-tumoral (right panels) regions. Each dot represents the mean of all acquired fields from the same tissue sample (at least 20 fields at magnification 20× for each stained slide).

Article Snippet: The following primary antibodies were used for staining: anti-human CD3 rabbit polyclonal antibody (A0452, Dako, Glostrup, Denmark), at a concentration of 6 μg/mL; anti-human IL-17A goat polyclonal antibody (AF-317-NA, R&D Systems, Minneapolis, MN, USA), at 1:20 dilution; anti-human placenta growth factor (PlGF) rabbit polyclonal antibody (clone 1880, Santa Cruz Biotechnology, Santa Cruz, CA, USA), at 1:50 dilution.

Techniques: Multiplex Assay, Immunofluorescence, Staining

Journal: Biomedicines

Article Title: Reduced Interleukin-17-Expressing Cells in Cutaneous Melanoma

doi: 10.3390/biomedicines9121930

Figure Lengend Snippet: Multiplex immunofluorescence analysis of the second panel. ( a ) Representative 7-color multispectral image of the second multiplex immunofluorescence panel. Markers and color codes are indicated in the figure. Original magnification 20×. Single marker assessment is reported in the small pictures around the merged image. Density (number of cells/mm 2 ) of total IL-17A+ and IL-17A+PlGF+ cells ( b ), total CD8+ T lymphocytes, CD8+PlGF+ and CD8+IL-17A+ cells ( c ), total FoxP3+ T regulatory cells, FoxP3+PlGF+ and FoxP3+IL-17A+ cells ( d ), and total CD11b+, CD11b+PlGF+ and CD11b+IL-17A+ cells ( e ) was quantified in the stroma (left panels) and in the intra-tumoral (right panels) regions. Each dot represents the mean of all acquired fields from the same tissue sample (at least 20 fields at magnification 20× for each stained slide).

Article Snippet: The following primary antibodies were used for staining: anti-human CD3 rabbit polyclonal antibody (A0452, Dako, Glostrup, Denmark), at a concentration of 6 μg/mL; anti-human IL-17A goat polyclonal antibody (AF-317-NA, R&D Systems, Minneapolis, MN, USA), at 1:20 dilution; anti-human placenta growth factor (PlGF) rabbit polyclonal antibody (clone 1880, Santa Cruz Biotechnology, Santa Cruz, CA, USA), at 1:50 dilution.

Techniques: Multiplex Assay, Immunofluorescence, Marker, Staining